On October 1, 2019 Avidity Biosciences, a privately-held biotechnology company pioneering Antibody Oligonucleotide Conjugates (AOCs), reported the appointment of global business leader Sarah Boyce as President and Chief Executive Officer and a member of the Avidity Board of Directors (Press release, Avidity Biosciences, OCT 1, 2019, View Source [SID1234539967]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are delighted to welcome Sarah as the new CEO of Avidity Biosciences," said Troy Wilson, Ph.D., J.D., Executive Chairman of the Board of Directors, co-founder and founding CEO of Avidity. "Sarah’s broad experience in the healthcare industry, combined with her strategic expertise and track record of leading high-performance teams, position her to be a great partner to both the board and management as we continue to advance our pipeline, optimize our AOC platform and prepare to initiate our first clinical study."

Ms. Boyce brings to Avidity extensive experience in the life sciences industry, where she has built global organizations and brought to patients a number of innovative therapies, including Tegsedi, Waylivra, Soliris, Gleevec and Tasigna. She most recently served as President and a member of the board of directors of Akcea Therapeutics, where she led commercialization of the company’s rare disease products. Prior to joining Akcea in April 2018, Ms. Boyce held multiple executive-level roles at leading pharma and biotech companies including Ionis Pharmaceuticals, Forest Laboratories, Alexion Pharmaceuticals, Novartis Oncology and Roche.

"I am honored by the opportunity the board has extended and am excited to lead Avidity through its next phase of growth," said Sarah Boyce, President and CEO of Avidity Biosciences. "I look forward to working with the leadership team and the board to continue to expand the proprietary AOC technology which combines the benefits of two innovative therapeutic approaches into a pioneering platform and to usher the first wave of potential therapeutics into the clinic."

On October 1, 2019 Amyris, Inc. (Nasdaq: AMRS) reported highlights of its business and financial results for the first half of 2019 ended June 30, 2019, which it will review during a conference call after market close on Wednesday, October 2, 2019 (Press release, Amyris Biotechnologies, OCT 1, 2019, View Source [SID1234539999]). The company also noted that it is has filed its 2018 Form 10-K and expects to file its Form 10-Qs for the first and second quarters of 2019 before the conference call on Wednesday. As a result of completing these filings, the company believes that it will have filed all of its delinquent SEC filings and be back in compliance with Nasdaq listing rules.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

First-Half 2019 Financial Results and Recent Business Highlights

First-half 2019 GAAP revenue of $77.1 million with very strong gross margin compared to total first-half 2018 GAAP revenue of $32.9 million
Successful launch of Pipette baby care brand raising the bar for clean and safe baby care products
International expansion of Biossance, one of the fastest growing clean beauty skincare brands in the US, gets a strong start upon entry into Australian and New Zealand markets
Expansion of ADL Bionatur Solutions (ADL) manufacturing agreement and execution of strategic supply agreement with Raízen, the largest sugar producer in the world, to provide additional, cost-effective manufacturing capacity to meet growth demand
Appointment of two new board members with significant experience in building high growth product and consumer companies ‒ Jim McCann, founder and chairman of 1-800-Flowers, and Lisa Qi, founder and CEO of Daling Family e-commerce platform in China
Receipt of first milestone payment of $10 million in March 2019 for successful cannabinoid (CBD) development; good progress being made toward second major milestone
"We are pleased with our financial results for the first-half of 2019," said John Melo, Amyris President and CEO. "Our teams have delivered higher volumes to support stronger demand this year and in the second half they are continuing at record levels. We remain confident that we will exceed our revenue goal for 2019. Our $300 million cannabinoid development collaboration is also exceeding our expectations. We are now on track to be the first company to produce multiple cannabinoids at commercial scale that are fermentation derived in 2020."

The company will hold its conference call to discuss financial results and business highlights for the first half of 2019, as well as provide an update on the company’s business and outlook, at 4:30 p.m. ET (1:30 p.m. PT) on Wednesday, October 2, 2019. The company will not be issuing a customary earnings release on its financial results prior to the call, as the company expects that the financial results for the first and second quarters of 2019 will have been fully disclosed via the filing of required Form 10-Qs.

Conference Call:
Wednesday, October 2, 2019, 4:30 p.m. ET/1:30 p.m. PT

Dial-in Number:
(877) 870-4263 (U.S. & International)

Participants should ask to be joined to the Amyris, Inc. call.

Audio Webcast:
A live webcast of the call will be available online on the Amyris website. To listen via live webcast, please visit: View Source A replay of the webcast will be available on the Investor Relations section of the company’s website approximately two hours after the conclusion of the call.

On October 1, 2019 Constellation Pharmaceuticals, Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, reported that it has entered into a securities purchase agreement with a group of institutional investors for the private placement of $65 million of shares of its common stock (Press release, Constellation Pharmaceuticals, OCT 1, 2019, View Source [SID1234539968]). The transaction is expected to close on or about October 3, 2019, subject to the satisfaction of customary closing conditions. The private placement is being led by Venrock Healthcare Capital Partners and includes Bain Capital Life Sciences and affiliates of The Column Group.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In this private placement, the Company is selling 7,647,057 shares of common stock at a price of $8.50 per share. The Company expects to use net proceeds from the private placement to fund research and development expenses, including the clinical development of CPI-0610, CPI-1205 and CPI-0209, to advance the current pipeline of preclinical candidates, to discover and develop additional preclinical product candidates using its platform, as well as for working capital and other general corporate purposes.

The securities to be sold in the private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdictions’ securities laws. The Company has agreed to file a registration statement with the U.S. Securities and Exchange Commission (the "SEC") registering the resale of the shares of common stock issued in the private placement no later than the 75th day after the closing of the private placement.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any offer, solicitation or sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. Any offering of the securities under the resale registration statement will only be made by means of a prospectus.

On October 1, 2019 CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, reported that members of its senior management team are scheduled to make the following presentations in October (Press release, CRISPR Therapeutics, OCT 1, 2019, View Source [SID1234539984]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Chardan’s 3rd Annual Genetic Medicines Conference
Date: Tuesday, October 8, 2019
Presentation: 10:30 a.m. ET
Location: New York, NY

Jefferies Gene Therapy/Editing Summit
Date: Tuesday, October 8, 2019
Panel Discussion: 1:10 p.m. ET
Location: New York, NY

A live webcast of the events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of the webcast will be archived on the Company’s website for 14 days following the presentation.

On October 1, 2019 AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, reported that it will be presenting at the following investor, oncology and regenerative medicine conferences in October (Press release, AIVITA Biomedical, OCT 1, 2019, View Source [SID1234540000]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cell & Gene Meeting on the Mesa
Company Presentation
Time: October 2, 11:00 AM PST
Location: Park Hyatt Aviara Resort Golf Club & Spa, Cognate in the Bioservices Ballroom, Carlsbad, CA

World Immunotherapy Congress
Keynote Title: Enhancing patient responses with autologous cancer stem cell vaccine in combination with checkpoint inhibitors
Time: October 16, 9:25 AM CET
Location: Congress Centre Basel, Basel, Switzerland

BIO Investor Forum
Company Presentation
Time: October 23, 10:15 AM PST
Location: Elizabethan A, The Westin St. Francis, San Francisco, CA

World Vaccine Congress
Talk Title: Autologous Cancer Stem Cell Vaccines for Solid Tumor Cancers
When: October 29, 3:45 PM CET
Location: Palau de Congressos de Catalunya, Barcelona, Spain